A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(22 sites)

China

Beijing Cancer Hospital, Beijing, Beijing Municipality

Japan

Shikoku Cancer Center, Matsuyama, Ehime

Gunma Prefectural Cancer Center, Ota-Shi, Gunma

Kure Medical Center And Chugoku Cancer Center, Kure, Hirosima [Hiroshima]

Teine Keijinkai Hospital, Sapporo, Hokkaido